The Lancet最新文献

{"title":"Reflecting on progress, envisioning the future for research in Down syndrome","authors":"Jonathan D Santoro, Michael S Rafii","doi":"10.1016/s0140-6736(25)00510-0","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)00510-0","url":null,"abstract":"No Abstract","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143666232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives","authors":"Jan Versijpt, Koen Paemeleire, Uwe Reuter, Antoinette MaassenVanDenBrink","doi":"10.1016/s0140-6736(25)00109-6","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)00109-6","url":null,"abstract":"Almost 40 years ago, the discovery of the vasoactive neuropeptide calcitonin gene-related peptide (CGRP) and its role in migraine pathophysiology ushered in a new era in migraine treatment. Since 2018, monoclonal antibodies (mAbs) targeting the CGRP pathway are available for migraine prevention. The approval of these drugs marks a pioneering development, as they are the first pharmacological agents specifically tailored for migraine prevention. Introduction of these agents contrasts the historical reliance on traditional preventive medications initially formulated for other indications and later repurposed for migraine therapy. Although the emergence of evidence on the efficacy and safety of CGRP-targeted mAbs has raised the bar for treatment success in migraine, their efficacy in other headache entities, such as cluster headache, is low to moderate. Small-molecule CGRP receptor antagonists called gepants have also been proven to be effective both as acute and preventive migraine treatments. Furthermore, these agents have bridged the traditional categories of acute and preventive treatment strategies. Short-term prevention and treatment during the prodromal phase of migraine represent emerging strategies enabling clinicians to develop treatment approaches designed to meet changing patient needs; however, these strategies still require more formal evidence. Although solid data have been gathered, further research concerning the efficacy and long-term safety of drugs targeting the CGRP pathway and robust pharmacoeconomic evaluations are needed. Finally, randomised withdrawal and switching studies would facilitate the formulation of evidence-based guidance for the discontinuation of and switching between drugs targeting the CGRP pathway.","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143666225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The demise of USAID: time to rethink foreign aid?","authors":"","doi":"10.1016/s0140-6736(25)00556-2","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)00556-2","url":null,"abstract":"No Abstract","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143666234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thank you to The Lancet statistical and peer reviewers in 2024","authors":"","doi":"10.1016/s0140-6736(25)00512-4","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)00512-4","url":null,"abstract":"No Abstract","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143666238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Department of Error","authors":"","doi":"10.1016/s0140-6736(25)00519-7","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)00519-7","url":null,"abstract":"<em>Bretherton CP, Achten J, Jogarah V, et al. Early versus delayed weight-bearing following operatively treated ankle fracture (WAX): a non-inferiority, multicentre, randomised controlled trial.</em> Lancet <em>2024;</em> 403: <em>2787–97—</em>In this Article, the spelling of author Henry Claireaux's name has been corrected. This correction has been made to the online version as of March 20, 2025","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143666241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can we diagnose and manage suspected acute brain infections better?","authors":"Alfred Kongnyu Njamnshi, Eric Samuel Chokote","doi":"10.1016/s0140-6736(25)00468-4","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)00468-4","url":null,"abstract":"No Abstract","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143666235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wolves and women's bodies | My Good Bright Wolf: A Memoir, Sarah Moss, Picador (2025), p. 320, £10·99, ISBN: 9781035035823","authors":"Margaret McCartney","doi":"10.1016/s0140-6736(25)00517-3","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)00517-3","url":null,"abstract":"No Abstract","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143666228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thank you to The Lancet's reviewers in 2024","authors":"","doi":"10.1016/s0140-6736(25)00461-1","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)00461-1","url":null,"abstract":"No Abstract","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143666236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cecile Richards","authors":"Jacqui Thornton","doi":"10.1016/s0140-6736(25)00518-5","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)00518-5","url":null,"abstract":"<span><figure><span><img alt=\"\" aria-describedby=\"alt11\" height=\"445\" src=\"https://ars.els-cdn.com/content/image/1-s2.0-S0140673625005185-fx1.jpg\"/><span aria-hidden=\"true\">NEW YORK, NY - DECEMBER 12: Cecile Richards attends Hearst Chief Content Officer Joanna Coles Hosts the Hearst 100 Luncheon at Michael's on December 12, 2016 in New York City. (Photo by Jared Siskin/Patrick McMullan via Getty Images)</span><ol><li><span><span>Download: <span>Download high-res image (335KB)</span></span></span></li><li><span><span>Download: <span>Download full-size image</span></span></span></li></ol></span></figure></span>","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"115 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143666229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Misleading marketing claims fuel tapentadol prescriptions","authors":"Madlen Davies, Hristio Boytchev, Rafael Cabrera","doi":"10.1016/s0140-6736(25)00552-5","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)00552-5","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Industry-funded studies</h2>Since tapentadol's introduction in 2008, Grünenthal, its licensees, or researchers who receive funding from these companies have published articles suggesting tapentadol causes less dependence, addiction, or abuse.The Examination sent five of the studies to medical experts who identified a variety of shortcomings. A 2014 CNS Drugs review by Grünenthal employees claimed the “reduced dependence seen with tapentadol” might be due to its dual mechanism, but experts said there was no evidence for</section></section><section><section><h2>Promoted as less addictive</h2>Company employees have perpetuated misleading messages about the drug. At least seven former Grünenthal employees in Germany and the UK promoted tapentadol as less likely to cause dependence.One pharmaceutical representative who left Grünenthal in 2023 after 6 years and did not want to be named out of fear for her career, said Grünenthal taught sales representatives to promote the drug to doctors as less likely to cause dependence using study data, written materials, and seminars. Lack of</section></section><section><section><h2>“It's pure nonsense”</h2>A video on Grünenthal's educational site for health-care professionals across Latin America featured Silvia Allende-Pérez, head of a public pain clinic in Mexico and former Grünenthal employee. In it, she promoted tapentadol and its “advantages over other opioids”, and included a Grünenthal-branded slide claiming tapentadol has a “minimum potential of abuse”. The slide also said “respiratory depression, not reported” despite this condition being a well known side-effect of opioids. Grünenthal</section></section><section><section><h2>Escalating harms</h2>Tapentadol sales and prescriptions have risen around the globe in recent years in at least ten countries, including Germany, the USA, and Mexico, according to data collected by The Examination. In Spain, tapentadol prescriptions have now surpassed oxycodone. In Australia, tapentadol has become the most prescribed opioid and CSL Seqirus, which holds the licence, boasted last year that it was the “only opioid with consistent growth”.<span><figure></figure></span>Simon Gill, a pharmacist and independent</section></section>","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143666240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}